Focused On-demand Library for DNA primase small subunit

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P49642

UPID:
PRI1_HUMAN

ALTERNATIVE NAMES:
DNA primase 49 kDa subunit

ALTERNATIVE UPACC:
P49642

BACKGROUND:
The DNA primase small subunit is integral to the DNA primase complex, initiating DNA synthesis by creating RNA primers. Its function is vital during the S phase of the cell cycle, ensuring accurate DNA replication. This protein's ability to incorporate ribonucleotides in the presence of both ribo- and deoxy-nucleotide triphosphates is essential for the replication process.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Primordial dwarfism-immunodeficiency-lipodystrophy syndrome, the DNA primase small subunit is a key target for therapeutic intervention. Exploring its mechanisms could lead to groundbreaking therapies for diseases caused by genetic mutations in DNA replication processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8634 of 8789